Skip to main content
SpringerLink
Log in

Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif

Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Le trastuzumab (Herceptine®, Roche) a complètement révolutionné le pronostic du cancer du sein HER2 positif, que ce soit en situation métastatique, adjuvante ou néoadjuvante. Cependant, des résistances acquises apparaissent le plus souvent, dont les mécanismes potentiels sont multiples. Deux agents ont récemment fait leur apparition dans l’arsenal thérapeutique du cancer du sein HER2 positif: le pertuzumab (Perjeta®, Roche) et le T-DM1 (Kadcyla®, Roche). Nous présentons dans cette revue de la littérature les mécanismes d’action, les données précliniques, les données cliniques, le profil de tolérance et les études en cours concernant ces deux thérapies.

Abstract

Trastuzumab (Herceptin®, Roche) completely revolutionized the outcome of patients with HER2-positive breast cancer, in the metastatic, adjuvant and neoadjuvant setting. However, acquired resistances appear mostly, whose potential mechanisms are multiple. Two agents recently appeared: pertuzumab (Perjeta®, Roche) and T-DM1 (Kadcyla ®, Roche). In this review of the literature, we present the mechanisms of action, the pre-clinical data, the clinical data, the safety and the ongoing studies regarding these two therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fr|Références

  1. Slamon DJ, Clark GM, Wong SG, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235: 177–82

    Article  CAS  PubMed  Google Scholar 

  2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–37

    Article  CAS  PubMed  Google Scholar 

  3. Agus DB, Akita RW, Fox WD, et al. (2002) Targeting ligandactivated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127–37

    Article  CAS  PubMed  Google Scholar 

  4. Lee-Hoeflich ST, Crocker L, Yao E, et al. (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68: 5878–87

    Article  CAS  PubMed  Google Scholar 

  5. Nahta R, Hung MC, Esteva FJ (2004) The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343–6

    Article  CAS  PubMed  Google Scholar 

  6. Scheuer W, Friess T, Burtscher H, et al. (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69: 9330–6

    Article  CAS  PubMed  Google Scholar 

  7. Agus DB, Gordon MS, Taylor C, et al. (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534–43

    Article  CAS  PubMed  Google Scholar 

  8. Yamamoto N, Yamada Y, Fujiwara Y, et al. (2009) Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (pertuzumab, RO4368451) in Japanese patients with solid tumors. Jpn J Clin Oncol 39: 260–6

    Article  PubMed Central  PubMed  Google Scholar 

  9. Attard G, Kitzen J, Blagden SP, et al. (2007) A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumors. Br J Cancer 97: 1338–43

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Albanell J, Montagut C, Jones ET, et al. (2008) A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors. Clin Cancer Res 14: 2726–31

    Article  CAS  PubMed  Google Scholar 

  11. Baselga J, Gelmon KA, Verma S, et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–44

    Article  CAS  PubMed  Google Scholar 

  12. Portera CC, Walshe JM, Rosing DR, et al. (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14: 2710–6

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Cortes J, Fumoleau P, Bianchi GV, et al. (2012) Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30: 1594–600

    Article  CAS  PubMed  Google Scholar 

  14. Baselga J, Cortes J, Kim SB, et al. (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366: 109–19

    Article  CAS  PubMed  Google Scholar 

  15. Miles DBJ, Amadori D, Sunpaweravong P, et al. (2012) Pertuzumab in combination with trastuzumab and docetaxel in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

  16. Dakto FDAG, Dickler M, Theodoulou M, et al. (2012) Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in aptients with metastatic HER2-overexpressing metastatic breast cancer. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

  17. Gianni L, Pienkowski T, Im YH, et al. (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NEOSPHERE): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25–32

    Article  CAS  PubMed  Google Scholar 

  18. Schneeweiss A, Chia S, Hickish T, et al. (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomised phase II cardiac safety study (TRYPHAENA). Ann Oncol 24: 2278–84. doi: 10.1093/annonc/mdt182. Epub 2013 May 22

    Article  CAS  PubMed  Google Scholar 

  19. Kuramochi Y, Guo X, Sawyer DB (2006) Neuregulin activates ErbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41: 228–35

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Fedele C, Riccio G, Malara AE, et al. (2012) Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 134: 595–602

    Article  CAS  PubMed  Google Scholar 

  21. Lenihan D, Suter T, Brammer M, et al. (2012) Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab. Ann Oncol 23: 791–800

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Drucker AM, Wu S, Dang CT, et al. (2012) Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. Breast Cancer Res Treat 135: 347–54

    Article  CAS  PubMed  Google Scholar 

  23. Henjes F, Bender C, von der Heyde S, et al. (2012) Strong EGFR signaling in cell line models of ErbB2-amplified breast cancer attenuates response towards ErbB2-targeting drugs. Oncogenesis 1: e16

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Baselga J, Cortés J, Im SA, et al. (2014) Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer. J Clin Oncol 32: 3753–61

    Article  CAS  PubMed  Google Scholar 

  25. Gianni LBG, Kiermaier A, Bianchi G, et al. (2011) Neoadjuvant pertuzumab and trastuzumab: biomarker analyses of a 4-arm randomised phase II study (NEOSPHERE) in patients with HER2 positive breast cancer. In: San Antonio Breast Cancer Symposium, Texas, US, 2011

    Google Scholar 

  26. Gianni LBG, Valagussa P, Belousov A, et al. (2012) Adaptative immune system and immune checkpoints are associated with response to pertuzumab and trastuzumab in the NEOSPHERE study. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

  27. Junttila TT, Li G, Parsons K, et al. (2011) Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128: 347–56

    Article  CAS  PubMed  Google Scholar 

  28. Barok M, Tanner M, Koninki K, et al. (2011) Trastuzumab-DM1 causes tumor growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res 13: R46

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Lewis Phillips GD, Li G, Dugger DL, et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–90

    Article  CAS  PubMed  Google Scholar 

  30. Girish S, Gupta M, Wang B, et al. (2012) Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 69: 1229–40

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  31. Aogi KAM, Iwata H, Hara F, et al. (2011) Phase I study of single agent trastuzumab emtansine in Japanese patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (JO22591). In: San Antonio Breast Cancer Symposium, Texas, US, 2011

    Google Scholar 

  32. Beeram M, Krop IE, Burris HA, et al. (2012) A phase I study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer 118: 5733–40

    Article  CAS  PubMed  Google Scholar 

  33. Krop IE, Beeram M, Modi S, et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28: 2698–704

    Article  CAS  PubMed  Google Scholar 

  34. Burris HA 3rd, Rugo HS, Vukelja SJ, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)- positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29: 398–405

    Article  PubMed  Google Scholar 

  35. Krop IE, LoRusso P, Miller KD, et al. (2012) A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 30: 3234–41

    Article  CAS  PubMed  Google Scholar 

  36. Masuda NIY, Takao S, Doihara H, et al. (2012) A multicenter phase 2 study (JO22997) evaluating the efficacy and safety of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive metastatic breast cancer. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

  37. Hurvitz SA, Dirix L, Kocsis J, et al. (2013) Phase II randomised study of trastuzumab emtansine vs trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31: 1157–63

    Article  CAS  PubMed  Google Scholar 

  38. Verma S, Miles D, Gianni L, et al. (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–91

    Article  CAS  PubMed  Google Scholar 

  39. Olson EM, Lin NU, DiPiro PJ, et al. (2012) Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol 23: 93–7

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Dieras VHN, Budd GT, Greenson JK, et al. (2012) Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

  41. Thon JN, Devine MT, Jurak Begonja A, et al. (2012) Highcontent live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1): mediated inhibition of platelet production. Blood 120: 1975–84

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  42. Bender BC, Schaedeli-Stark F, Koch R, et al. (2012) A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 70: 591–601

    Article  CAS  PubMed  Google Scholar 

  43. Fields CTCL, Sliwkowski MX, Lewis Phillips GD (2010) Dual targeting of HER2: enhanced antitumor efficacy of trastuzumab-DM1 combined with pertuzumab. In: AACR, Washington, US, 2010

    Google Scholar 

  44. Dieras VHN, Albain K, Burris H, et al. (2010) A phase Ib/II trial of trastuzumab-DM1 with pertuzumab for patients with HER2- positive, locally advanced or metastatic breast cancer: interim efficacy and safety results In: San Antonio Breast Cancer Symposium, Texas, US, 2010

    Google Scholar 

  45. Miller KGL, André F, Dieras V, et al. (2010) A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive locally advanced or metastatic breast cancer who were previously treated with trastuzumab. In: American Society of Clinical Oncology Annual Meeting, Chicago, US, 2010

    Google Scholar 

  46. Martin MGSJ, Dewar JA, Albanell J, et al. (2012) Interim results from a phase Ib/IIa study of trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive locally advanced or metastatic breast cancer. In: San Antonio Breast Cancer Symposium, Texas, US, 2012

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’oncologie médicale, centre Georges-François-Leclerc, 1, rue du Professeur-Marion, F-21000, Dijon, France

    S. Guiu & P. Fumoleau

Authors
  1. S. Guiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Fumoleau
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Guiu.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guiu, S., Fumoleau, P. Pertuzumab et T-DM1 : de nouvelles perspectives dans le traitement du cancer du sein HER2 positif. Oncologie 17, 263–270 (2015). https://doi.org/10.1007/s10269-015-2484-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-015-2484-5

Mots clés

Keywords

Search

Navigation